WO2002013874A8 - Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen - Google Patents

Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Info

Publication number
WO2002013874A8
WO2002013874A8 PCT/EP2001/008498 EP0108498W WO0213874A8 WO 2002013874 A8 WO2002013874 A8 WO 2002013874A8 EP 0108498 W EP0108498 W EP 0108498W WO 0213874 A8 WO0213874 A8 WO 0213874A8
Authority
WO
WIPO (PCT)
Prior art keywords
necroses
tumours
plaques
imaging
representation
Prior art date
Application number
PCT/EP2001/008498
Other languages
English (en)
French (fr)
Other versions
WO2002013874A2 (de
Inventor
Johannes Platzek
Peter Mareski
Ulrich Niedballa
Bernd Raduechel
Hanns-Joachim Weinmann
Bernd Misselwitz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Priority to JP2002519012A priority Critical patent/JP2004506025A/ja
Priority to CA002419223A priority patent/CA2419223A1/en
Priority to PL01365596A priority patent/PL365596A1/xx
Priority to BR0113188-5A priority patent/BR0113188A/pt
Priority to KR10-2003-7002023A priority patent/KR20030022387A/ko
Priority to AU2001277549A priority patent/AU2001277549B2/en
Priority to UA2003032067A priority patent/UA82642C2/uk
Priority to EP01955366A priority patent/EP1307236A2/de
Priority to HU0300736A priority patent/HUP0300736A3/hu
Application filed by Schering Ag filed Critical Schering Ag
Priority to IL15438501A priority patent/IL154385A0/xx
Priority to EEP200300061A priority patent/EE200300061A/xx
Priority to NZ523932A priority patent/NZ523932A/en
Priority to MXPA03001287A priority patent/MXPA03001287A/es
Priority to AU7754901A priority patent/AU7754901A/xx
Priority to SK157-2003A priority patent/SK1572003A3/sk
Publication of WO2002013874A2 publication Critical patent/WO2002013874A2/de
Publication of WO2002013874A8 publication Critical patent/WO2002013874A8/de
Priority to NO20030604A priority patent/NO20030604L/no
Priority to BG107542A priority patent/BG107542A/bg
Priority to HR20030173A priority patent/HRP20030173A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PCT/EP2001/008498 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen WO2002013874A2 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SK157-2003A SK1572003A3 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in MR-imaging for the representation of plaques, tumours and necroses
EEP200300061A EE200300061A (et) 2000-08-11 2001-07-23 Perfluoroalküülrühmi sisaldavad metallikompleksidkasutamiseks kontrastainetena magnetresonantskuvamisel naastude, kasvajate ja nekrooside visualiseerimiseks
IL15438501A IL154385A0 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
NZ523932A NZ523932A (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in MR-imaging for the representation of plaques, tumours and necroses
CA002419223A CA2419223A1 (en) 2000-08-11 2001-07-23 Use of perfluoroalkyl-containing metal complexes as contrast media in mr-imaging for visualization of plaques, tumours and necroses
AU2001277549A AU2001277549B2 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
UA2003032067A UA82642C2 (uk) 2000-08-11 2001-07-23 Застосування перфторалкілвмісних комплексів металів як контрастних речовин в магнітно-резонансній томографії для візуалізації бляшок, пухлин і некрозів
EP01955366A EP1307236A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen
HU0300736A HUP0300736A3 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mri-imaging for the representation of plaques, tumours and necroses
JP2002519012A JP2004506025A (ja) 2000-08-11 2001-07-23 プラーク、腫瘍および壊死を造影するための、ｍｒ−イメージングにおける造影剤としてのペルフルオロアルキル含有金属錯体の使用
PL01365596A PL365596A1 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
KR10-2003-7002023A KR20030022387A (ko) 2000-08-11 2001-07-23 플라크, 종양 및 괴사를 가시화하기 위한ｍｒ-영상기술에서 조영제로서의 퍼플루오로알킬 함유금속 착물의 용도
BR0113188-5A BR0113188A (pt) 2000-08-11 2001-07-23 Aplicação de complexos de metal contendo perfluoroalquila como agentes de contraste na imagem de ressonância magnética para a identificação de placas, tumores e necroses
MXPA03001287A MXPA03001287A (es) 2000-08-11 2001-07-23 Uso de complejos metalicos conteniendo perfluoroalquilo como medios de contraste en imagenes rm para la representacion de placas, tumores y necrosis.
AU7754901A AU7754901A (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
BG107542A BG107542A (bg) 2000-08-11 2003-02-07 Използване на перфлуороалкил съдържащи метални комплекси като контрастни средства за изображения при ядрено магнитен резонанс и представяне на плаки,тумори и некрози
NO20030604A NO20030604L (no) 2000-08-11 2003-02-07 Anvendelse av perfluoralkylholdige metallkomplekser som kontrastmiddel vedMR-avbildning for å påvise plakk, tumorer og nekroser
HR20030173A HRP20030173A2 (en) 2000-08-11 2003-03-10 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumors and necroses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10040380.8 2000-08-11
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques

Publications (2)

Publication Number Publication Date
WO2002013874A2 WO2002013874A2 (de) 2002-02-21
WO2002013874A8 true WO2002013874A8 (de) 2002-06-13

Family

ID=7652860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Country Status (26)

Country Link
EP (1) EP1307236A2 (de)
JP (1) JP2004506025A (de)
KR (1) KR20030022387A (de)
CN (1) CN1469757A (de)
AR (1) AR034139A1 (de)
AU (2) AU7754901A (de)
BG (1) BG107542A (de)
BR (1) BR0113188A (de)
CA (1) CA2419223A1 (de)
CZ (1) CZ2003392A3 (de)
DE (1) DE10066210B4 (de)
EE (1) EE200300061A (de)
HR (1) HRP20030173A2 (de)
HU (1) HUP0300736A3 (de)
IL (1) IL154385A0 (de)
MX (1) MXPA03001287A (de)
NO (1) NO20030604L (de)
NZ (1) NZ523932A (de)
PL (1) PL365596A1 (de)
RU (1) RU2290206C2 (de)
SK (1) SK1572003A3 (de)
TW (1) TWI296931B (de)
UA (1) UA82642C2 (de)
WO (1) WO2002013874A2 (de)
YU (1) YU10603A (de)
ZA (1) ZA200301949B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (de) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Neue gadoliniumchelat-verbindung zur verwendung in der magnetresonanzbildgebung
WO2018052037A1 (ja) 2016-09-14 2018-03-22 ダイキン工業株式会社 分枝含フッ素化合物
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
KR20210095168A (ko) 2018-11-23 2021-07-30 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
JPH10112939A (ja) * 1996-10-07 1998-04-28 Nec Corp 電源切替回路
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
CA2419223A1 (en) 2003-02-11
ZA200301949B (en) 2004-12-14
PL365596A1 (en) 2005-01-10
EE200300061A (et) 2004-12-15
AU2001277549B2 (en) 2007-02-08
MXPA03001287A (es) 2003-10-06
HUP0300736A2 (hu) 2003-09-29
KR20030022387A (ko) 2003-03-15
CN1469757A (zh) 2004-01-21
EP1307236A2 (de) 2003-05-07
BG107542A (bg) 2003-09-30
NZ523932A (en) 2007-07-27
HRP20030173A2 (en) 2005-04-30
DE10066210B4 (de) 2008-02-28
CZ2003392A3 (cs) 2003-09-17
RU2290206C2 (ru) 2006-12-27
SK1572003A3 (en) 2003-10-07
AU7754901A (en) 2002-02-25
WO2002013874A2 (de) 2002-02-21
BR0113188A (pt) 2003-06-24
AR034139A1 (es) 2004-02-04
NO20030604D0 (no) 2003-02-07
HUP0300736A3 (en) 2010-01-28
UA82642C2 (uk) 2008-05-12
YU10603A (sh) 2006-05-25
IL154385A0 (en) 2003-09-17
TWI296931B (en) 2008-05-21
JP2004506025A (ja) 2004-02-26
NO20030604L (no) 2003-04-11

Similar Documents

Publication Publication Date Title
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
IT1313599B1 (it) Complessi metallici utilizzabili nella catalisi per la (co)polimerizzazione delle alfa-olefine
WO2002013874A8 (de) Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
IL158985A0 (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
EP1465997A4 (de) Verwendung biomolekularer ziele bei der behandlung und sichtbarmachung von tumoren
EP1482985A4 (de) Technetium-dipyridin-komplexe und anwendungsverfahren dafür
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
EP1435988A4 (de) Verbesserte verwendung einer antitumoralen verbindung in der krebstherapie
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
EP1390689A4 (de) Verminderung kohärenter artefakte in einem interferometer
AU2002328323A1 (en) 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy
AU2002213883A1 (en) Cr complexes and their use for the polymerization of alpha-olefins
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003233431A1 (en) Protamine-adenoviral vector complexes and methods of use
EP1416945A4 (de) Verbesserte heteropolymer-komplexe und verfahren zu ihrer verwendung
IL152388A0 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
CA2481005A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
AU2001284299A1 (en) Pyrazolone lanthanide complexes
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer
AU2002354738A1 (en) Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-106/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

D17 Declaration under article 17(2)a
WWE Wipo information: entry into national phase

Ref document number: 2001955366

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 523932

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1572003

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 10754201

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2003-392

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002519012

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037002023

Country of ref document: KR

Ref document number: 2419223

Country of ref document: CA

Ref document number: 03010932

Country of ref document: CO

Ref document number: PA/a/2003/001287

Country of ref document: MX

Ref document number: 154385

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 183/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001277549

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/01949

Country of ref document: ZA

Ref document number: P20030173A

Country of ref document: HR

Ref document number: 200301949

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 1020037002023

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018172717

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001955366

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-392

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001955366

Country of ref document: EP